Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Meta Expands AI Training With Employee Activity Tracking Tools 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
BERKELEY, Calif., Feb. 24, 2016 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, March 9, 2016, at 4:30 p.m. Eastern Standard Time to discuss fourth quarter and full year 2015 financial results and provide an update on its endocrine disease portfolio.
The webcast can be accessed via the Investors & Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on May 9, 2016. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.
CONTACT: Investor Contacts:
Ashleigh Barreto, XOMA
510-204-7482
[email protected]
Juliane Snowden, The Oratorium Group, LLC
[email protected]
Media Contact:
Ryan Flinn, W2O Group
415-946-1059
[email protected]
